Clinical trials: Non-hodgkin Lymphoma,B Cell
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
- Trial name
- NCT03684694
- Testing
- Loncastuximab Tesirine, Ibrutinib
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 136 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
CT-011 MAb in DLBCL Patients Following ASCT
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease.
- Conditions
- Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT00532259
- Testing
- CT-011
- Where
- 27 sites in United States, India and 1 more
- Volunteers
- 72 people
- Sponsor
- CureTech Ltd
Lymphoma, Non-Hodgkin Lymphoma
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas.
- Conditions
- Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
- Trial name
- NCT03223610
- Testing
- Venetoclax, Ibrutinib, Prednisone
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Diffuse Large B-Cell Lymphoma
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of…
- Trial name
- NCT07059650
- Testing
- DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR
- Where
- 13 sites in China
- Volunteers
- 150 people
- Sponsor
- Dizal Pharmaceuticals
Diffuse Large B-cell Lymphoma(DLBCL)
A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression
Zanubrutinib is a highly specific, potent new Bruton's tyrosine kinase （BTK） inhibitor, with minimal off-target inhibition of other kinases.
- Trial name
- NCT05189197
- Testing
- Zanubrutinib + R-CHOP
- Where
- China
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Fudan University
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase I/II trial is studying the side effects and the best dose of obatoclax mesylate when given together with rituximab and bendamustine hydrochloride to see how well it works compared with rituximab and bendamustine…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma
- Trial name
- NCT01238146
- Testing
- bendamustine hydrochloride, obatoclax mesylate, rituximab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma
- Trial name
- NCT06047197
- Testing
- RC19D2 cell injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Yongtai Ruike Biotechnology Company Ltd
Marginal Zone B-cell Lymphoma
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma (SMZL) is a well-defined low-grade B-cell lymphoma,considered as a rare neoplasm accounting for about 2% of all non-Hodgkin's lymphomas (NHL) and represents for most cases of otherwise…
- Trial name
- NCT02853370
- Testing
- Bendamustine and Rituximab
- Where
- 30 sites in France, Italy
- Volunteers
- 78 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A phase I/IIa, open-label, single-center, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and preliminary efficacy of IMV101 as a single agent in subjects with relapsed/refractory B-cell non-Hodgkin…
- Trial name
- NCT07376642
- Testing
- IMV101 treatment
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
B-cell Non-Hodgkins Lymphoma (B-NHL)
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug[s]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs).
- Trial name
- ATHENA-1 (NCT05685173)
- Testing
- Odronextamab, REGN5837
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 107 people
- Sponsor
- Regeneron Pharmaceuticals
Aggressive Non-Hodgkin Lymphoma
Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
This is a phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas
- Trial name
- NCT03161054
- Testing
- Prednisone, Vinorelbine, Etoposide
- Where
- 10 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma
Long-Term Follow-up Study
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT.
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- LTFS (NCT05332054)
- Testing
- Caribou-sponsored investigational therapy
- Where
- 31 sites in United States
- Volunteers
- 150 people
- Sponsor
- Caribou Biosciences, Inc.
Lymphoma
Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00039351
- Testing
- cyclophosphamide, prednisone, vincristine sulfate
- Where
- 17 sites in Belgium, Egypt and 5 more
- Volunteers
- 32 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe…
- Trial name
- NCT05660395
- Testing
- Loncastuximab Tesirine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 5 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, B-Cell, Autologous Stem Cell Transplantation
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
- Trial name
- NCT06381830
- Testing
- Apheresis, Autologous Stem Cell Transplantation, CAR-T Cell Therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Chemotherapeutic Agent Toxicity, Lymphoma
Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
RATIONALE: Drugs used in chemotherapy, such as methotrexate and leucovorin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chemotherapeutic Agent Toxicity, Lymphoma, Mucositis, Neurotoxicity
- Trial name
- NCT00727831
- Testing
- glucarpidase, leucovorin calcium, methotrexate
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02892695
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
NHL, DLBCL - Diffuse Large B Cell Lymphoma
Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCL
A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene…
- Trial name
- HOVON161 (NCT05641428)
- Testing
- ARI-0001, Axi-cel
- Where
- 7 sites in Netherlands
- Volunteers
- 340 people
- Sponsor
- University Medical Center Groningen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.